In haste: The Hindu Editorial on vaccinating children against COVID-19
The HinduThe emergency use authorisation granted on April 26 to two COVID-19 vaccines — Corbevax for children 5-11 years, and Covaxin for children 6-11 years — is one more instance where the Indian drug regulator has acted in haste. Even if the EUA granted to Covaxin in January 2021 despite no safety and efficacy data of the phase-3 trial is condoned as a desperate measure in ensuring greater vaccine availability, the regulator clearly has no fig leaf to defend the greenlighting of the vaccines for children at this stage. The ICMR’s fourth seroprevalence survey soon after the second wave peaked nationally found that 57.2% of children and 61.6% of children were infected by SARS-CoV-2 virus; seroprevalence among adults was 66.7%. The Health Ministry had already set a precedent last month by clearing Corbevax for children 12-14 years without first seeking the approval of the National Technical Advisory Group on Immunisation, which clears vaccines for the national immunisation programme.